Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Also Read: What's Going On With Eli Lilly Stock On Tuesday? The trial, which enrolled more than 13,000 participants and lasted more than four and a half years, is the largest and longest study of tirzepatide to date, the company said in a statement on Thursday. In addition, while not controlled for multiplicity-adjusted type-1 error, Mounjaro showed improvements on key measures of A1C, weight, renal function, and all-cause mortality. In the trial, the risk of cardiovascular death, heart attack, or stroke wa ...